- CEO
- Wei Hong
- Full Time Employees
- 461
- Sector
- Consumer non-durables
- Industry
- Food: specialty/candy
- Address
- No. 151 Lihong Road Shanghai SH China 201807
- IPO Date
- Jun 17, 2022
- Business
- Shanghai Menon Animal Nutrition Technology Co., Ltd. engages in the research, development, production, and sale of feed additives and enzymatic protein feed raw materials primarily in China with exports to Asia, Europe, North America, South America, Africa, Oceania, and other international markets; founded in 1997 and headquartered at No. 151 Lihong Road, Jiading District, Shanghai, China. The company offers a comprehensive portfolio of products including food attractants, sweeteners, acidulants, plant extracts, sodium butyrate, butyric acid glyceride, emulsifiers, small peptides, fragrances, acidity regulators, flavoring agents such as Menaroma Fruity Series in flavors including banana, cherry almond, strawberry, raspberry, orange, apple, tutti frutti, and green grass, slow-release nitrogen sources, rumen-bypass amino acids, rumen-pass vitamins, mineral elements, and enzymatic hydrolysis of vegetable proteins; these solutions target animal breeding sectors for pigs, ruminants, poultry, and aquatic products, enhancing feed intake, palatability, gut health, nutrient absorption, and overall productivity while supporting antibiotic-free and sustainable farming practices. Recent developments include the commissioning of a dedicated production line for Menacid MT, a slow-release benzoic acid product that bolsters gut health and nutrient utilization in livestock; plans to establish a wholly-owned subsidiary for a 0.1 million ton annual corn protein processing project with an investment of approximately CNY 391 million; an investment agreement signed by its subsidiary with the Leling Economic Development Zone Management Committee in Shandong; establishment of a new company with CNY 100 million capital for biobased materials manufacturing; completion of a share repurchase program totaling 4.4068 million shares for CNY 61.0005 million; and a proposed 2025 restricted stock incentive plan alongside approval of an interim profit distribution plan.